Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSE-010 in Female C-IBS
NCT01056107Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2010
- Primary completion
- Dec 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LY307161 in irritable bowel syndrome (IBS) (4 arms), sponsored by Mayo Clinic. Primary endpoints: Colonic Transit, Colonic Geometric Center at 24 Hours, Change Between Postprandial and Fasting Whole Gastric Volume by Technetium-99m (99mTc)-SPECT Imaging and 1 more. Started Jan 2010; status: completed.
02
Drugs
LY307161
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT01056107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01056107.